NCT01830608

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of blindness in the Western World. The etiology and pathogenesis of this disease remain largely unknown. In Europe about two million people suffer from AMD. According to the Age-Related Eye Disease Study (AREDS) the disease can be classified into early, intermediate and late. Early age-related macular degeneration is characterized by the presence of small or medium-sized drusen and/or retinal pigmentary abnormalities. Intermediate age-related macular degeneration is characterized by large drusen or numerous medium-size drusen and/or geographic atrophy not extending to the center of the macula. Late age-related macular degeneration can be either atrophic with extension to the macula or neovascular. The late form of the disease is associated with a pronounced loss of visual acuity. In the recent years several studies focused on risk factors for late AMD and a recent systematic review and meta-analysis reported risk factors for AMD based on 16 studies in almost 114000 subjects. Strong and consistent associations with late AMD for found for increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD. Consistent associations between late AMD and higher body mass index, history of cardiovascular disease, hypertension and higher plasma fibrinogen were also found, but the association was weak. Inconsistent associations were found for gender, ethnicity, diabetes, iris color, history of cerebrovascular disease, serum total and HDL cholesterol and triglyceride levels. Evidence has also accumulated that other factors influence the risk for AMD. Several genetic risk factors have been identified in the last years including genes in the alternative complement pathway and the RMS2/HTRA1 region. In addition, post-hoc analysis of data from the AREDS study has indicated that reduced intake of the omega-3 free fatty acids eicosapentaenoic acid and docsahexaenoic acid are associated with the risk of late AMD thereby supporting previous population based studies. The AREDS study also revealed that reduced intake of the macular pigment lutein and zeaxanthin may be associated with late AMD, again supporting previous population-based studies. Finally, 2 small studies indicate that reduced choroidal blood flow is associated with an increased risk of developing late AMD. Less data are available for the progression of early or intermediate AMD and the associated risk factors. This is at least partially related to the problems in quantifying progression of drusen size and volume. In the recent years, however, significant efforts have been achieved in optical coherence tomography (OCT)-based methods for quantifying drusen progression and drusen volume. Polarization-sensitive OCT is the most promising of these approaches and will be used to quantify drusen area and volume in the present study.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2015

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 12, 2013

Completed
1.7 years until next milestone

Study Start

First participant enrolled

January 1, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2015

Completed
Last Updated

April 8, 2015

Status Verified

April 1, 2015

Enrollment Period

2 months

First QC Date

April 10, 2013

Last Update Submit

April 7, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Drusen area and volume as measured using polarization sensitive-OCT

    3 years

Secondary Outcomes (3)

  • Visual acuity and refraction

    3 years

  • Choroidal blood flow

    3 years

  • Macular pigment optical density

    3 years

Study Arms (1)

300 patients with AMD

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

300 male and female patients with age-related macular degeneration

You may qualify if:

  • Men and postmenopausal women aged ≥ 50 years
  • AREDS categories 2 or 3 in at least one of the eyes
  • No ocular surgery within last 6 months

You may not qualify if:

  • Late form of AMD in one or two eyes (AREDS category 4)
  • Moderate or severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy
  • Clinically significant macular edema
  • Macular or peripheral retinal dystrophies
  • Ocular surgery other than uncomplicated cataract surgery
  • Opacity of the ocular media by cornea or lens or diseases, which could potentially influence scan quality

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, Vienna, 1090, Austria

Location

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass. Prof. Priv. Doz. Dr.

Study Record Dates

First Submitted

April 10, 2013

First Posted

April 12, 2013

Study Start

January 1, 2015

Primary Completion

March 1, 2015

Study Completion

March 1, 2015

Last Updated

April 8, 2015

Record last verified: 2015-04

Locations